Leerink Partners Reiterates Buy Rating for ABIVAX Socie9te9 Anonyme

Leerink Partners has reiterated its buy rating on ABIVAX Socie9te9 Anonyme (NasdaqGM: ABVX), maintaining a price target of $148. This update comes as ABIVAX shares traded at $132.83 on Tuesday.

Other Institutional Activity in ABIVAX Socie9te9 Anonyme

Institutional investors have been active in ABIVAX recently. TCG Crossover Management, LLC reduced its holdings by 630,511 shares, now holding 6,481,085 shares worth about $721.7 million, marking an 8.9% decrease. Meanwhile, UBS Group AG increased its stake by 123,500 shares, bringing its total to 4,547,406 shares valued at approximately $506.4 million, a 2.8% increase. Darwin Global Management, Ltd. added 290,156 shares to its portfolio, now holding 3,468,657 shares worth $352.1 million, a 9.1% increase. Morgan Stanley significantly reduced its position by 1,447,036 shares, leaving it with 1,704,958 shares valued at $189.8 million, a 45.9% decrease.

ABIVAX Société Anonyme Stock Up 18.6%

Shares of ABIVAX Socie9te9 Anonyme (NasdaqGM: ABVX) traded near $132.83 on Tuesday. The company, with a market cap of $7.78 billion, operates in the biotechnology industry. It has a 52-week low of $7.41 and a 52-week high of $148.83. The stock's 50-day moving average is $111.58, while the 200-day moving average is $111.21. ABIVAX has a current ratio of 8.25 and a quick ratio of 8.07, with a debt-to-equity ratio of 7.96.

Analysts Set New Price Targets

On June 30, 2026, Leerink Partners maintained its buy rating on ABIVAX Socie9te9 Anonyme with a price target of $148. BTIG also maintained a buy rating with a higher target of $175. Earlier in June, Truist Securities and Morgan Stanley both reiterated their buy ratings with targets of $135 and $132, respectively. The consensus among analysts is a buy, with a mean target price of $150.73 based on 11 opinions.

About ABIVAX Socie9te9 Anonyme

ABIVAX Socie9te9 Anonyme is a biotechnology company based in Paris, France. It focuses on developing treatments that leverage the body's natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases. The company's leading drug candidate, obefazimod, is in Phase 3 clinical trials for treating ulcerative colitis and Phase 2b trials for Crohn's disease. Founded in 2013, ABIVAX is led by CEO Marc M. P. de Garidel and employs about 80 people.

Bottom Line

Leerink Partners' reiterated buy rating and target price of $148 reflect ongoing confidence in ABIVAX Socie9te9 Anonyme's prospects. Investors closely watch such ratings for insights into potential stock performance. As always, it's important to remember that analyst ratings are opinions and should be considered alongside other information when evaluating investments.